Evaluating Liraglutide in Alzheimer's Disease
NCT01843075 on ClinicalTrials.gov · last registry update 2019-06-10
204 participants. Its estimated completion date, December 2019, has passed with no update to the record. Primary outcome, as filed: The change in cerebral glucose metabolic rate. A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. liraglutide is approved in the US, but not for neurodegenerative — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- UNKNOWN
- Phase
- P2
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- Imperial College London
- Sponsor type
- Other
- Enrollment
- 204
- Started
- 2014-01
- Primary completion
- 2019-12 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
The change in cerebral glucose metabolic rate
Conditions studied
Alzheimer's Disease
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.